A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilisation and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD).
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2013
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 15 Oct 2008 Actual start date changed from Nov 2004 to Dec 2004 as reported by Clinicaltrials.gov
- 15 Oct 2006 New trial record.